Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Meeting Report
  • Published:

Meeting report: myelodysplastic syndromes at ASH 2007

Leukemia volume 22, pages 893–897 (2008)Cite this article

Abstract

Myelodysplastic syndromes (MDS) remain challenging to both clinicians and biologists. This year's edition of the Annual Meeting of the American Society of Hematology has provided several breakthroughs in the biology and therapeutics of MDS, such as uncovering of the molecular genetics of the 5q− syndrome and clear evidence of a survival advantage with a hypomethylating agent in high-risk MDS. We summarize those advances and delineate some perspectives for these diseases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465.

    Article  CAS  Google Scholar 

  2. Boultwood J, Fidler C, Strickson AJ, Watkins F, Gama S, Kearney L et al. Narrowing and genomic annotation of the commonly deleted region of the 5q−syndrome. Blood 2002; 99: 4638–4641.

    Article  CAS  Google Scholar 

  3. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758–764.

    Article  CAS  Google Scholar 

  4. Joslin JM, Fernald AA, Tennant TR, Davis EM, Kogan SC, Anastasi J et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 2007; 110: 719–726.

    Article  CAS  Google Scholar 

  5. Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 2007; 13: 78–83.

    Article  Google Scholar 

  6. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N et al. Identification of RPS14 as a 5q−syndrome gene by RNA interference screen. Nature 2008; 451: 335–339.

    Article  CAS  Google Scholar 

  7. Craven SE, French D, Ye W, de Sauvage F, Rosenthal A . Loss of Hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndrome. Blood 2005; 105: 3528–3534.

    Article  CAS  Google Scholar 

  8. Choesmel V, Bacqueville D, Rouquette J, Noaillac-Depeyre J, Fribourg S, Cretien A et al. Impaired ribosome biogenesis in Diamond–Blackfan anemia. Blood 2007; 109: 1275–1283.

    Article  CAS  Google Scholar 

  9. Bilanges B, Stokoe D . Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies. Oncogene 2007; 26: 5973–5990.

    Article  CAS  Google Scholar 

  10. Wan F, Anderson DE, Barnitz RA, Snow A, Bidere N, Zheng L et al. Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation. Cell 2007; 131: 927–939.

    Article  CAS  Google Scholar 

  11. Braun T, Carvalho G, Coquelle A, Vozenin MC, Lepelley P, Hirsch F et al. NF-kappaB constitutes a potential therapeutic target in high risk myelodysplastic syndrome. Blood 2006; 107: 1156–1165.

    Article  CAS  Google Scholar 

  12. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005; 8: 355–368.

    Article  CAS  Google Scholar 

  13. Dutt A, Beroukhim R . Single nucleotide polymorphism array analysis of cancer. Curr Opin Oncol 2007; 19: 43–49.

    Article  CAS  Google Scholar 

  14. Deeg HJ . Marrow stroma in MDS: culprit or bystander? Leuk Res 2002; 26: 687–688.

    Article  Google Scholar 

  15. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25: 4246–4254.

    Article  Google Scholar 

  16. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503–3510.

    Article  Google Scholar 

  17. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594–7603.

    Article  Google Scholar 

  18. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586–4588.

    Article  CAS  Google Scholar 

  19. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895–3903.

    Article  CAS  Google Scholar 

  20. Garcia-Manero G . Modifying the epigenome as a therapeutic strategy in myelodysplasia. Hematology (Am Soc Hematol Educ Program) 2007; 2007: 405–411.

    Article  Google Scholar 

  21. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A . The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000; 96: 3932–3938.

    CAS  Google Scholar 

  22. Boudard D, Vasselon C, Bertheas MF, Jaubert J, Mounier C, Reynaud J et al. Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. Am J Hematol 2002; 70: 115–125.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’hématologie clinique, Hôpital Avicenne, Bobigny, France

    R Itzykson, C Gardin & P Fenaux

Authors
  1. R Itzykson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Gardin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Fenaux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Fenaux.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Itzykson, R., Gardin, C. & Fenaux, P. Meeting report: myelodysplastic syndromes at ASH 2007. Leukemia 22, 893–897 (2008). https://doi.org/10.1038/leu.2008.45

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.45

Keywords

Search

Advanced search

Quick links